Heteromerization of the gamma c Chain with the Interleukin-9 Receptor alpha  Subunit Leads to STAT Activation and Prevention of Apoptosis*

Johannes H. BauerDagger §, Kathleen D. Liu§par , Yun You§, Stephen Y. Lai§**, and Mark A. Goldsmith§Dagger Dagger

From the Dagger  Institute for Biochemistry, Free University Berlin, 14195 Berlin, Germany and § Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, California 94141-9100

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Interleukin-9 (IL-9) is a cytokine with pleiotropic effects on mast cell and T cell lines. It exerts its effects through the IL-9R complex consisting of IL-9Ralpha and the common gamma c subunit. Here we report functional evidence for receptor heteromerization for efficient signal transduction, and we define minimal requirements in the two receptor subunits for IL-9R function. Tyrosine 336 of the IL-9Ralpha and the membrane-proximal segment of gamma c are both crucial for signaling. The activated IL-9R complex employs the Janus kinases JAK1 and JAK3 for subsequent activation of the signal transducer and activator transcription (STAT) factors STAT-1, STAT-3, and STAT-5. This process is independent of Tyk2. We demonstrate further that the activated STAT complexes consist of STAT-1 and STAT-5 homodimers and STAT-1-STAT-3 heterodimers. Finally, we show that IL-9R signaling in a T cell line does not result in detectable mitogen-activated protein kinase activation and leads to unsustained proliferation. Nonetheless, these T cells are efficiently protected from dexamethasone-induced apoptosis. These results further define the molecular architecture of the IL-9R and its specific connections to various biologic responses.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

IL-91 is a pleiotropic cytokine secreted by activated T cells of the TH2 class (for review see Renauld et al. (1)). It is a major factor for mast cell differentiation, but its activity on T cells is less well characterized. It was shown to induce granzyme A and B expression in T cell lines (2). IL-9 is not mitogenic for freshly isolated T cells, but it is active on preactivated T cells and T cell lines (3). In addition, IL-9 stimulates in vitro growth of T cell lymphomas (4), and IL-9 transgenic mice show increased occurrence of thymic lymphomas (5). In humans, dysregulated IL-9 expression has been found in patients with Hodgkin's disease (6) and an autocrine IL-9 loop for proliferation has been demonstrated in Hodgkin's lymphoma-derived cell lines (7). Furthermore, it has been shown that IL-9 can protect thymic lymphoma cells and T cell lines from dexamethasone-induced apoptosis (8, 9). These data together suggest a possible role for IL-9 in tumorigenesis.

IL-9 exerts its effects through the functional IL-9R complex, consisting of IL-9Ralpha (10) and the common gamma c subunit. The gamma c subunit is also utilized in the receptor complexes for IL-2, IL-4, IL-7, and IL-15 (11-14). Both IL-9Ralpha and gamma c are members of the hematopoietin receptor superfamily (15), which share several common motifs, including four canonically spaced cysteine residues and the WSXWS motif in the extracellular domain, and the Box1 and Box2 motifs in the intracellular domain. The IL-9Ralpha was shown previously to associate with gamma c in the presence of IL-9 (16), and evidence for functional interaction of the two receptor chains was derived from studies in which anti-gamma c antibody treatment abolished IL-9R signaling (17).

Although neither receptor chain has any intrinsic kinase activity, rapid tyrosine phosphorylation of both receptor chains and cellular substrates occurs after receptor engagement. This step is thought to be mediated by the nonreceptor protein tyrosine kinases of the Janus kinase (JAK) family, which are preassociated with the receptor chains (for reviews, see Refs. 18 and 19). Stimulation of the IL-9R was shown to lead to the phosphorylation of JAK1, JAK3, and Tyk2 (20). It remained unclear, however, which of these kinases are necessary for the generation of the signaling response. Phosphorylated tyrosines of the receptor act as docking sites for STAT proteins (signal transducer and activator of transcription), that bind phosphotyrosines via SH2 domains (21, 22). Once bound, they become tyrosine-phosphorylated, dissociate from the receptor, and form homo- or heterodimers with members of their own family via SH2 domain interactions. These activated transcription factor dimers are capable of translocation into the nucleus to bind to specific DNA elements and initiate transcription of target genes. Several studies have suggested that the STATs involved in IL-9R signaling are STAT-1, STAT-3, and STAT-5 (20, 23, 24). However, the specific composition of the STAT·DNA complexes remained unclear.

The major activity of IL-9 on T cells has been proposed to be protection from apoptosis rather than mitogenesis. This has been demonstrated for thymic lymphoma cell lines (8) and T cell lines (9). However, no evidence has been obtained regarding the mechanisms underlying this antiapoptotic activity of the activated IL-9R.

In the present study chimeric receptors between the erythropoietin (EPO) extracellular domain and the IL-9Ralpha and gamma c intracellular domains were created and tested, along with several mutants of these chimeras, in COS-7 cells. The role of JAKs in IL-9R signaling was investigated in the human fibrosarcoma cell lines U4A and U1A that are deficient in JAK1 and JAK3, and JAK3 and Tyk2, respectively. Using these systems, the minimal requirements for IL-9R signaling were defined. Finally, a murine T helper cell line was stably transfected with chimeric receptors, and the effect of receptor stimulation was investigated by assays for STAT-DNA binding, antiapoptotic activity, and proliferation. These data suggest that signaling through the IL-9R blocks dexamethasone-induced activation of components of the cell death machinery, possibly due to activation of the antiapoptotic STAT-3 and STAT-5.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Lines and Reagents-- The IL-2-dependent murine T helper cell line HT-2 (ATCC) was cultured in RPMI 1640, supplemented with 10% fetal bovine serum, 55 µM 2-mercaptoethanol, 2 mM L-glutamine, and 200 units/ml recombinant human IL-2. Transfections were performed by electroporation (950 µF, 300 V, on a Bio-Rad Genepulser II) using 1 × 107 cells and 20 mg of DNA; stable transfectants were obtained by selection in G418 (1 mg/ml, Life Technologies, Inc.). Clones isolated by limiting dilution were screened by Northern blot analysis to identify cell lines stably expressing the transfected receptor subunit. Stable transfectants expressing two receptor subunits were derived from cells already expressing either EPOgamma or EPOgamma YF; clones were obtained by selection in G418 and hygromycin B (Boehringer Mannheim) and screened by Northern blot analysis.

COS-7 monkey kidney cells (ATCC) were routinely cultured in Iscove's medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine. Transfections were carried out in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine using LipofectAMINE (Life Technologies, Inc.) per the manufacturer's instructions.

U4A and U1A human fibrosarcoma cells (a kind gift of Dr. G. Stark) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and hygromycin B. Transfections were carried out using the calcium phosphate method (Life Technologies, Inc.).

Anti-STAT-3 and anti-STAT-5 antisera were obtained from Santa Cruz Biotechnology. Anti-STAT-1 monoclonal antibody was obtained from Transduction Laboratories, antiphosphotyrosine monoclonal antibody (4G10) from Upstate Biotechnology. Recombinant murine IL-9 was purchased from Genzyme; recombinant human EPO was a kind gift of Ortho Biotech Inc., and recombinant human IL-2 was a kind gift of the Chiron Corp.

Plasmids and Constructs-- All receptor cDNAs were subcloned into the expression vectors pCMV4, pCMV4neo, or pCMV4hygro. Chimeric EPOgamma and receptor mutants were generated as described elsewhere (25). The EPO9 chimera was constructed in a similar way using a NheI site at the fusion junction between EPOR extracellular domain and the transmembrane region of the human IL-9Ralpha . The EPO9Y3F mutant was generated using polymerase chain reaction overlap methodology as described previously (25). Native human IL-9Ralpha cDNA was a kind gift of Dr. J.-C. Renauld.

Proliferation Assays-- Conventional 72-h [3H]thymidine incorporation assays were performed using triplicate cultures of 5 × 104 cells per sample. Cells were incubated for the indicated time period with the indicated amount of factor. 1 µCi of [3H]thymidine was added for the last 4 h of incubation. Data are expressed as a percentage of [3H]thymidine incorporation of cells treated with 10 nM IL-2.

Apoptosis Assays-- 5-10 × 106 cells were incubated for 24 h in medium without IL-2, or stimulated with 10 nM IL-2, 50 units/ml EPO, or 1 µM dexamethasone (Sigma), respectively. Cells were harvested, washed with phosphate-buffered saline, and immediately used for staining. Staining with fluorescein isothiocyanate-conjugated annexin 5 and propidium iodide was performed using the ApoAlert kit (CLONTECH). Samples were analyzed on a Becton Dickinson FACScan. The percentage of dead (annexin 5- and propidium iodine-positive cells) and actively dying cells (annexin 5-positive and propidium iodide-negative) was determined by gating on the intact cell population, excluding cellular debris.

Electrophoretic Mobility Shift Assays (EMSA)-- 20-40 × 106 cells were rested in serum-free medium containing 1% bovine serum albumin for 4 h and stimulated as described for 10 min (COS-7, U4A, U1A) or 15 min (HT-2). Cells were lysed, and nuclear extracts were prepared as described previously (26).

DNA binding studies were performed with 1 × 105 cpm of probe, 3 µg of poly(dI-dC) (Boehringer Mannheim) and the indicated amounts of nuclear extracts on a nondenaturing 5% polyacrylamide gel. The IgG Fc receptor STAT response element (Fcgamma R1) was end-labeled with [gamma -32P]dATP (Amersham Corp.) and polynucleotide kinase (New England Biolabs). Preincubations with different antibodies were performed in the absence of poly(dI-dC) and binding buffer for 45 min on ice prior to initiation of the binding reaction by addition of labeled probe.

MAPK Assay-- 10-20 × 106 cells were rested for 6 h and stimulated as described. In vitro MAPK assays were performed using the MAPK assay kit (New England Biolabs). In short, cells were lysed and activated Erk1/Erk2 MAPK was immunoprecipitated using an antiphospho-MAPK antibody. Kinase assays were performed using an Elk1-glutathione S-transferase fusion protein as a substrate with subsequent immunoblotting for phosphorylated Elk1.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Reconstitution of IL-9R Function in COS-7 Cells-- To evaluate the minimal requirements for efficient signaling in the IL-9R system a chimeric receptor approach was employed in the background of COS-7 cells. Expression plasmids encoding EPO9 (chimeric IL-9Ralpha subunit containing extracellular domain of EPOR) and EPOgamma (chimeric gamma c chain containing extracellular domain of EPOR) were cotransfected into these cells together with various components of the signaling machinery and STAT activation was investigated. After stimulation with EPO, nuclear extracts were prepared, followed by EMSA with a STAT-specific binding element (Fcgamma R1). DNA binding activity was observed only when both chimeric receptor chains EPO9 and EPOgamma were present (Fig. 1A), and was not detected when either receptor chain alone was present. Thus, signaling through the IL-9R apparently depends on heteromultimerization of the two receptor subunits; based on the structure of EPOR these presumably represent dimers, but higher order multimers may exist. Endogenous JAKs and cotransfected JAK3 were necessary and sufficient for the generation of a signal by this receptor complex. In the absence of cotransfected STAT, a single band corresponding to endogenous STAT-1 (as identified by antibody supershift analysis, data not shown) was present; cotransfection of STAT-5 resulted in a second more slowly migrating band, which was identified as STAT-5 by antibody supershift analysis (data not shown). These data show that EPO9 and EPOgamma apparently must form heteromers for efficient signal transduction resulting in STAT binding to DNA. This signaling complex requires JAK3 and is able to activate both STAT-1 and STAT-5.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Induction of STAT factors in a COS transfection system. COS-7 cells were transfected with the indicated expression plasmids, and nuclear extracts were analyzed by EMSA with the Fcgamma R1 STAT binding element. A, DNA binding of STAT factors occurred in the presence of both receptor chains and cotransfected JAK3. Upon cotransfection of STAT-5, a second, more slowly migrating, band appeared. U, unstimulated; E, EPO-stimulated. B, various mutants of EPOgamma were investigated for their ability to induce STAT DNA binding, including a cytoplasmic truncation with retention of both Box1 and Box2 motifs (EPOgamma 336) and mutants in which either the Box1 or Box2 motif was deleted (EPOgamma 294, EPOgamma Delta Box1, EPOgamma Delta Box2). C, complete substitution of the tyrosines of EPOgamma to phenylalanine (EPOgamma YF) did not result in a change of STAT DNA binding pattern. The Y3F mutation in the EPO9 receptor, however, abolished DNA binding of all STAT factors. The upper arrow indicates cotransfected STAT-5, the lower endogenous STAT-1.

To test which portions of gamma c are necessary for efficient signaling, several mutants of EPOgamma (25) were tested (Fig. 1B). The EPOgamma 336 mutant, with C-terminal truncation up to the Box2 region, supported induction of both STAT-1 and STAT-5 bands and thus showed no difference compared with the wild-type chain in the EMSA. Further truncation into the Box1-Box2 (EPOgamma 294) domain and to the TM region (EPOgamma TM), or internal deletion of either Box1 or Box2, abolished signaling. Since JAK3 has been proposed to bind to the Box1-Box2 domain of gamma c, these results likely are explained by the inability of those mutants to bind JAK3.

Tyrosine substitution mutants of both receptor chains were tested to elucidate the role of tyrosine residues in the signaling processes (Fig. 1C). Complete substitution of all tyrosines in the EPOgamma chain with phenylalanine (EPOgamma YF) led to no change in STAT activation. EPO9Y3F was created to verify in this system the recent report that tyrosine 336 of IL-9Ralpha is important for STAT activation and antiapoptotic signaling (24). Substitution of tyrosine 336 with phenylalanine (EPO9Y3F) in EPO9 led to the loss of both STAT bands following receptor stimulation (Fig. 1C). These results indicate that tyrosines of gamma c are dispensable for signaling by the IL-9R, whereas tyrosine 336 of IL-9Ralpha is crucial for activation of STAT-1 and STAT-5.

Reconstitution of Native IL-9R Function-- To confirm these findings and to clarify further the role of the JAKs in IL-9R function, U4A and U1A cells were employed in a similar reconstitution approach. U4A is a somatic mutant of the human 2FTGH cell line that fails to express JAK3 and JAK1 but contains JAK2 and Tyk2 (27). In U4A cells, IL-9-mediated induction of STAT-5 was reconstituted by the simultaneous transfection of IL-9Ralpha , gamma c, JAK1, JAK3, and STAT-5 (Fig. 2). No signal was observed when any of these components were omitted from the transfection, indicating that endogenous Tyk2 or JAK2 cannot substitute for JAK1 or JAK3 in this system (Fig. 2). Furthermore, replacement of either wild-type JAK1 or JAK3 with a kinase-inactive mutant that lacks the catalytic lysine (JAK1 K907A or JAK3 K851A, respectively) (28) abolished downstream induction of STAT-5. These findings strongly suggest that the primary kinases required for IL-9R function are JAK1 and JAK3, and that Tyk2 is dispensable for this activity.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Reconstitution of native receptor complexes in somatic cell mutant lines. U4A or U1A cells were transfected as indicated, stimulated with 100 units/ml murine IL-9, and EMSA was performed as described. Extracts derived from U4A cells showed DNA binding activity only when IL-9Ralpha and plasmids encoding gamma c, JAK1, JAK3, and STAT-5 were cotransfected. Catalytically defect variants of JAK1 (JAK1KA) or JAK3 (JAK3KA) did not efficiently substitute for wild-type JAK1 or JAK3, respectively. E denotes endogenous expression of Tyk2.

To establish definitively whether or not Tyk2 contributes to IL-9R function in this system, similar experiments were performed with the U1A somatic mutant (29) that lacks Tyk2 and JAK3 but retains JAK1 and JAK2. In this cellular context, robust activation of STAT-5 through the IL-9R occurred upon introduction of JAK3 (Fig. 2); Tyk2 evidently was nonessential for this process since these cells lack Tyk2. Transfection with a Tyk2 expression plasmid in place of JAK3 yielded only a very marginal signal (Fig. 2). Therefore, complementary systems (COS, U4A, and U1A) uniformly demonstrated the importance of catalytically active JAK1 and JAK3 and the dispensability of Tyk2 for IL-9R-dependent signaling.

Signaling by a Chimeric IL-9R Induces STAT-1, STAT-3, and STAT-5 in a T Cell Line-- The EPO9 and EPOgamma /EPOgamma YF receptor chains were stably transfected into the IL-2-dependent murine T helper cell line HT-2 to investigate IL-9R signaling in a T cell context. After stimulation of stable transfectants with EPO, nuclear extracts were prepared and analyzed by EMSA with the Fcgamma R1 probe. DNA binding activity was detected only in cells expressing both chimeric receptor chains, EPO9 and EPOgamma (Fig. 3). The resulting triple band vanished when excess unlabeled oligonucleotide was used as a competitor. STAT activation was sustained over a 60-min stimulation period, and the signal became weaker with prolonged stimulation vanishing after 90 min (data not shown). The tripartite band was also observed in cells transfected with vectors encoding EPO9 and EPOgamma YF (Fig. 3). To determine further the nature of the observed bands, supershift analysis was performed with antibodies against phosphotyrosine and against STAT-1, STAT-3, and STAT-5 (Fig. 3). Isotype-matched antibodies resulted in no change of pattern. Treatment with antiphosphotyrosine antibodies resulted in a complete loss of all three bands, due to prevention of formation of STAT dimers via SH2 domain-phosphotyrosine interactions. When extracts were treated with anti-STAT-1 antibody, the two lower bands were lost, whereas anti-STAT-3 treatment led to selective loss of the middle band and some diminution of the lower band. Anti-STAT-5 antibody resulted in slower migration of the upper band. The anti-STAT-1 and anti-STAT-3 antibodies presumably are blocking antibodies, preventing either STAT-dimer formation or DNA binding, resulting in loss of the band. In contrast, the anti-STAT-5-antibody apparently binds to the STAT-5·DNA complex, which leads to a slower migration of the band on the gel. These data suggest that the STAT complexes formed upon stimulation of the IL-9R consist of STAT-5 and STAT-1 homodimers (upper and lower bands, respectively), STAT-1-STAT-3 heterodimers (middle band), and possibly STAT-3 homodimers (bottom band).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Signaling in a transfected T cell line. After stimulation with EPO, nuclear extracts from HT-2 cells stably transfected with either a single chimeric receptor chain, or with both, were analyzed by EMSA as in Fig. 1. A, DNA binding activity was only observed in extracts from cells expressing both receptor chains EPOgamma /9 and EPOgamma YF/9. The resulting tripartite band vanished when 100-fold excess unlabeled Fcgamma R1 was used as a competitor for DNA binding. -, no stimulation; E, EPO; 2, IL-2. B, supershift analysis of extracts of HT-2-EPOgamma /9 was performed with the indicated antibodies to determine the nature of the observed bands. The upper arrow indicates STAT-5 homodimers, the middle arrow STAT-1-STAT-3 heterodimers, the lower arrow STAT-1 homodimers. The asterisk indicates the presumed STAT-5 homodimers supershifted by anti-STAT-5 antibody.

Signaling through the Chimeric IL-9R Complex Inhibits Dexamethasone-induced Apoptosis-- To test whether IL-9R stimulation protected HT-2 cells from glucocorticoid-induced apoptosis, stable cell lines were treated with dexamethasone and evaluated for apoptotic responses by flow cytometry analysis of cells stained with fluorescein isothiocyanate-labeled annexin 5. HT-2 cells were starved of IL-2 for 24 h and treated with either dexamethasone alone or with dexamethasone and EPO. IL-2 withdrawal, as well as additional dexamethasone treatment, led to the onset of apoptosis after ~4 h (data not shown), resulting in a massive number of apoptotic cells after 24 h (Fig. 4). Treatment with dexamethasone increased the percentage of dead and dying cells considerably above the level induced by IL-2 withdrawal. Stimulation of the chimeric receptor complex with EPO led to a complete blockade of apoptosis caused by dexamethasone, but had no influence on the degree of apoptosis caused by IL-2 starvation. EPO-mediated inhibition of dexamethasone-dependent apoptosis was not observed in cells expressing a single receptor subunit (EPOgamma or EPO9, Fig. 5, A and B, respectively), but only in cells expressing both EPO9 and EPOgamma or EPO9 and EPOgamma YF (Fig. 4, C and D, respectively).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Protection from apoptosis by the IL-9R. After 24 h of incubation with the indicated factors, the proportion of cells undergoing apoptosis was determined by annexin 5 staining. HT-2 cells expressing only one chimeric receptor subunit (EPOgamma , panel A; EPO9, panel B), underwent apoptosis in the absence of IL-2 and to a greater extent upon additional dexamethasone treatment. Stimulation with EPO of cells expressing both chimeric receptor chains (EPOgamma /9, panel C; EPOgamma YF/9, panel D) blocked dexamethasone-induced apoptosis, but not apoptosis caused by IL-2 withdrawal. Error bars are the standard error of the mean of triplicate measurements; in some cases these error bars are too small too be depicted.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of proliferation in a T cell line. Proliferative response of stably transfected HT-2 cells after stimulation with the indicated doses of EPO. A, cells expressing only a single receptor subunit did not respond to EPO after 24 h of stimulation. The double transfectants EPOgamma /9 and EPOgamma YF/9 responded to EPO vigorously in a dose-dependent manner. B, the proliferative response of HT-2 EPOgamma /9 and HT-2 EPOgamma YF/9 cells was time-dependent and was not sustained for more than 24 h. Additional dexamethasone treatment completely blocked the proliferative response to EPO (14 units/ml) of these cell lines; the same effects were observed at 10 or 50 units/ml (data not shown). Error bars are the standard error of the mean of triplicate measurements; in some cases these error bars are too small too be depicted.

The Signal Delivered by the Chimeric IL-9R Does Not Sustain Proliferation in HT-2 Cells-- Since reduction of the percentage of annexin 5-positive cells by treatment with EPO could have been due to an increased overall cell number, the proliferative signal generated by the IL-9R was investigated. HT-2 cells transfected with either EPO9 or EPOgamma alone displayed no proliferative response to EPO in the absence of IL-2 as measured by [3H]thymidine incorporation (Fig. 5). Both, EPOgamma /9 and EPOgamma YF/9, however, showed vigorous DNA synthesis after 24 h in a dose-dependent fashion. Nevertheless, this response was not sustained and diminished to background levels after 72 h (Fig. 5). Prolonged cultivation in EPO without IL-2 did not lead to generation of EPO-dependent clones.

Activation of Erk1/Erk2 MAPK Does Not Take Place in Response to EPO-- To test whether the proliferative response after chimeric receptor stimulation with EPO was associated with activation of MAPKs, in vitro kinase assays of immunoprecipitated Erk1/Erk2 MAPK were performed. Unstimulated HT-2 EPOgamma /9 cells showed no detectable MAPK activity as shown by Western blotting for in vitro phosphorylated Elk1 substrate (Fig. 6). However, upon stimulation with IL-2, strong activation of MAPK was observed. Stimulation of the chimeric EPOgamma /9 receptor complex with EPO did not result in substantial induction of MAPK activity. These data suggest that the signaling pathways leading to proliferation are different in the IL-2R and IL-9R systems, and apparently are incomplete in the IL-9R system in this cellular context.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 6.   Absence of MAPK induction by IL-9R in HT-2 cells. Total cell lysates of HT-2 EPOgamma /9 cells were prepared and immunoprecipitated with antiphospho-MAPK antibody. Immunoprecipitates were subjected to in vitro kinase assays with an Elk1-glutathione S-transferase fusion protein, separated by 10% SDS-polyacrylamide gel electrophoresis and immunoblotted with antiphospho-Elk1 antibodies. HT-2 EPOgamma /9 stimulation with IL-2 yielded a ~40-kDa band (indicated by the arrow) corresponding to phosphorylated Elk1, whereas EPO stimulation did not.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

These studies demonstrate that the functional IL-9R complex consists of heteromers of gamma c and IL-9Ralpha , as confirmed in a variety of cellular backgrounds and by various measurements of signal transduction. In a T cell line, STAT activation, induction of DNA synthesis and protection from apoptosis were observed exclusively upon engagement of both receptor subunits. The data presented here with various mutants of the gamma c or IL-9Ralpha cytoplasmic tail are also consistent with the "trigger driver" model proposed for signaling by various chimeric cytokine receptors (30). In this model, the gamma c chain acts in the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors to initiate the signaling response upon engagement of ligand by conveying a kinase (JAK3) into the receptor complex. Within the IL-9R, the specificity of the resulting signaling response appears to be coupled to tyrosine residues within the IL-9Ralpha chain.

The IL-9R and its associated JAK1 and JAK3 apparently activate a specific signaling program involving STAT-1 homodimers, STAT-1-STAT-3 heterodimers and STAT-5 homodimers as shown by antibody supershift analysis of nuclear extracts of stable transfectants. Furthermore, activation of these STAT complexes is linked to tyrosine 336 of IL-9Ralpha and does not depend upon tyrosines of the gamma c subunit. Therefore, as in the IL-2, IL-4, and IL-7 receptors, specificity in the signaling program appears to be driven largely through the longer, non-gamma c subunit of the receptor.

Consistent with earlier studies demonstrating JAK1 and JAK3 activation (20, 23) by IL-9, these kinases were observed to be crucial for generating STAT·DNA complexes in the IL-9R system. In the U4A system, simultaneous transfection of both JAK1 and JAK3 (along with the receptor chains and STAT-5) effectively reconstituted IL-9-mediated STAT-5 induction. Since these cells express Tyk2 endogenously, it is evident that Tyk2 could not replace either JAK1 or JAK3 to support IL-9R function. Additionally, the catalytic integrity of both of these kinases was essential for IL-9R function. These findings are consistent with those observed in the reconstitution experiments, in which endogenous Tyk2 and JAK1 were insufficient to support IL-9R function. Moreover, experiments with the U4A cell line lacking Tyk2 revealed definitively the dispensability of Tyk2 for IL-9R function. Therefore, although Tyk2 may be activated detectably by IL-9 in some cellular contexts, it does not appear to play a major role in IL-9R signaling function.

IL-9R signals through chimeric receptors were found to stimulate short-term DNA synthesis of HT-2 cells. Strong proliferative effects of IL-9 have been observed only in mast cells and activated T-cells. Non-sustained proliferation, as observed here, could be due to a variety of signaling constraints that may be cell context-specific. The failure of the IL-9R to activate Erk1/Erk2 MAPK as measured in the short-term assay in this system is one such example, and other cell-specific pathways also need to be explored.

Perhaps the most important function mediated by IL-9 is prevention of apoptosis, which was shown here to depend upon dimerization of the IL-9Rgamma and gamma c subunits of the IL-9R. The molecular mechanism underlying the antiapoptotic effect remains to be elucidated. STAT-3 and/or STAT-5 may play a role, since they have been implicated in antiapoptotic effects in other signaling systems. For example, it was demonstrated that overexpression of a dominant-negative form of STAT-3 inhibited induction of the antiapoptotic gene bcl-2 upon stimulation of the IL-6R complex (31). Moreover, STAT-5 has been shown to bind to the activated glucocorticoid receptor and to inhibit glucocorticoid receptor-mediated gene transcription in COS-7 cells (32). Further studies are needed to clarify these and other possible mechanisms with regard to the IL-9R. Since apoptosis in general plays an important role in tissue homeostasis and regulation of the immune response (33), clarifying mechanisms by which immune regulatory cytokines exert antiapoptotic activity and proliferative actions remains an important goal. The system presented here should prove useful in addressing these questions.

    ACKNOWLEDGEMENTS

We thank Drs. Ian Kerr and George Stark for the U4A and U1A cell lines, Dr. Jean-Christophe Renauld for the human IL-9Ralpha cDNA, and Amy Corder, John Carroll, Brian Clark, and Jessica Diamond for their excellent help in preparing this manuscript. We also thank K. Mark Ansel for critical comments regarding this manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant R01 GM54351 (to M. A. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by a gift from Ligand Pharmaceuticals Inc. (to M. A. G.).

par Supported by the National Institutes of Health Medical Scientist Training Program and the Biological Sciences Program of the University of California, San Francisco.

** Supported by the National Institutes of Health Medical Scientist Training Program and the Biomedical Sciences Program of the University of California, San Francisco.

Dagger Dagger To whom correspondence should be addressed: Gladstone Institute of Virology and Immunology, P. O. Box 419100, San Francisco, CA 94141-9100. Tel.: 415-695-3775; Fax: 415-826-1514; E-mail: Mark_Goldsmith{at}quickmail.ucsf.edu.

1 The abbreviations used are: IL, interleukin; JAK, Janus kinase; STAT, signal transducer and activator of transcription; EPO, erythropoietin; EPOR, EPO receptor; MAPK, mitogen-activated protein kinase; Erk, extracellular signal-regulated kinase; EMSA, electrophoretic mobility shift assay.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Renauld, J. C., Kermouni, A., Vink, A., Louahed, J., and Van Snick, J. (1995) J. Leukoc. Biol. 57, 353-360[Abstract]
  2. Louahed, J., Kermouni, A., Van Snick, J., and Renauld, J.-C. (1995) J. Immunol. 154, 5061-5070[Abstract/Free Full Text]
  3. Uyttenhove, C., Simpson, R. J., and Van Snick, J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 6934-6938[Abstract]
  4. Vink, A., Renauld, J.-C., Warnier, G., and Van Snick, J. (1993) Eur. J. Immunol. 23, 1134-1138[Medline] [Order article via Infotrieve]
  5. Renauld, J.-C., van der Lugt, N., Vink, A., van Room, M., Godfraind, C., Warnier, G., Merz, H., Feller, A., Berns, A., and Van Snick, J. (1994) Oncogene 9, 1327-1332[Medline] [Order article via Infotrieve]
  6. Merz, H., Houssiau, F., Orscheschek, K., Renauld, J.-C., Fliedner, A., Herin, M., Noel, H., Kadin, M., Mueller-Hermelink, K. H., Van Snick, J., and Feller, A. C. (1991) Blood 78, 1311-1317[Abstract]
  7. Gruss, H. J., Brach, M. A., Drexler, H. G., Bross, K. J., and Herrman, F. (1992) Cancer Res. 52, 1026-1031[Abstract]
  8. Renauld, J.-C., Vink, A., Louahed, J., and Van Snick, J. (1995) Blood 5, 1300-1305
  9. Louahed, J., Renauld, J.-C., Demoulin, J.-B., Baughman, G., Bourgeois, S., Sugamura, K., and Van Snick, J. (1996) J. Immunol. 156, 3704-3710[Abstract]
  10. Renauld, J.-C., Druez, C., Kermouni, A., Houssiau, F., Uyttenhove, C., Van Roost, E., and Van Snick, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5690-5694[Abstract]
  11. Kondo, M., Takeshita, T., Ishii, N., Nakamura, M., Watanabe, S., Arai, K.-I., and Sugamura, K. (1993) Science 262, 1874-1877[Medline] [Order article via Infotrieve]
  12. Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., and Leonard, W. J. (1993) Science 262, 1877-1880[Medline] [Order article via Infotrieve]
  13. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., and Ahdieh, M. (1994) Science 264, 965-968[Medline] [Order article via Infotrieve]
  14. Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L. S., and Anderson, D. M. (1995) EMBO J. 14, 3654-3663[Abstract]
  15. Idzerda, R. L., March, C. J., Mosley, B., Lyman, S. D., Vanden Bos, T., Gimpel, S. D., Din, W. S., Grabstein, K. H., Widmer, M. B., Park, L. S., Cosman, D., and Beckmann, M. P. (1990) J. Exp. Med. 171, 861-873[Abstract]
  16. Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O., Goldman, A. S., Schmalstieg, F. C., Ihle, J. N., O'Shea, J. J., and Leonard, W. J. (1994) Science 266, 1042-1045[Medline] [Order article via Infotrieve]
  17. Kimura, Y., Takeshita, T., Kondo, M., Ishii, N., Nakamura, M., Van Snick, J., and Sugamura, K. (1995) Int. Immunol. 7, 115-120[Abstract]
  18. Darnell, J. E., Kerr, I. M., and Stark, G. R. (1994) Science 264, 1415-1421[Medline] [Order article via Infotrieve]
  19. Schindler, C., and Darnell, J. E. (1995) Annu. Rev. Biochem. 64, 621-651[CrossRef][Medline] [Order article via Infotrieve]
  20. Yin, T., Yang, L., and Yang, Y.-C. (1995) Blood 85, 3101-3106[Abstract/Free Full Text]
  21. Fu, X.-Y., Schindler, C., Improta, T., Aebersold, R., and Darnell, J. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7840-7843[Abstract]
  22. Schindler, C., Shuai, K., Prezioso, V. R., and Darnell, J. E. (1992) Science 257, 809-815[Medline] [Order article via Infotrieve]
  23. Yin, T., Keller, S. R., Quelle, F. W., Witthuhn, B. A., Tsang, M. L.-S., Lienhard, G. E., Ihle, J. N., and Yang, Y.-C. (1995) J. Biol. Chem. 270, 20497-20502[Abstract/Free Full Text]
  24. Demoulin, J.-B., Uyttenhove, C., Van Roost, E., de Lestre, B., Donckers, D., Van Snick, J., and Renauld, J.-C. (1996) Mol. Cell. Biol. 16, 4710-4716[Abstract]
  25. Goldsmith, M. A., Lai, S. Y., Xu, W., Amaral, M. C., Kuczek, E. S., Parent, L. J., Mills, G. B., Tarr, K. L., Longmore, G. D., and Greene, W. C. (1995) J. Biol. Chem. 270, 21729-21737[Abstract/Free Full Text]
  26. Gaffen, S. L., Lai, S. Y., Xu, W., Gouillex, F., Groner, B., Goldsmith, M. A., and Greene, W. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7192-7196[Abstract]
  27. Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., Pellegrini, S., Wilks, A. F., Ihle, J. N., Stark, G. R., and Kerr, I. M. (1993) Nature 366, 129-135[CrossRef][Medline] [Order article via Infotrieve]
  28. Liu, K. D., Gaffen, S. L., Goldsmith, M. A., and Greene, W. C. (1997) Curr. Biol. 7, 817-826[Medline] [Order article via Infotrieve]
  29. Velazquez, L., Fellous, M., Stark, G. R., and Pellegrini, S. (1992) Cell 70, 313-322[Medline] [Order article via Infotrieve]
  30. Smets, L. A., and van den Berg, J. (1996) Leuk. Lymphoma 20, 199-205[Medline] [Order article via Infotrieve]
  31. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., and Hirano, T. (1996) Immunity 5, 449-460[Medline] [Order article via Infotrieve]
  32. Stoecklin, E., Wissler, M., Gouilleux, F., and Groner, B. (1996) Nature 383, 726-728[CrossRef][Medline] [Order article via Infotrieve]
  33. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. (1980) Int. Rev. Cytol. 68, 251-306[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.